LM
PHAT icon

Luminus Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Luminus Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-126,903
Closed -$4.22M – 62
2020
Q4 		$4.22M Buy
+126,903
New +$5.14M 0.98% 22

Other funds holding PHAT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Luminus Management's PHAT Position: Q1 2021 in Review

Luminus Management sold out of Phathom Pharmaceuticals (PHAT) in Q1 2021, closing a stake of 126,903 shares — an estimated $4.22M sold.

Luminus Management first reported a position in PHAT in Q4 2020 and held it in 1 quarter. The position peaked at $4.22M in Q4 2020. 84 funds tracked by Wall St. Rank hold PHAT as of Q1 2021.

  • Luminus Management reported no remaining Phathom Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Luminus Management sold 126,903 Phathom Pharmaceuticals shares in Q1 2021, an estimated $4.22M.
  • Luminus Management first reported a position in Phathom Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Luminus Management's Phathom Pharmaceuticals position peaked at $4.22M in Q4 2020.
  • 84 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2021.

Based on Luminus Management's 13F filing for Q1 2021, filed 17 May 2021.